



### Remarks


In response to the Office Action date March 22, 2006, claims 1, 2, 4 and 15 are amended. Claims 3, 5, 7-14, 16, 18 and 20-26 are canceled without prejudice. No new matter has been added. After entry of this amendment, claims 1,2, 4, 6, 15, 17 and 19 are pending.


### **Claim Amendment**

Claims 1, 2 and 4 have been amended to comply with the restriction requirement. In particular, Applicants would like to point out that in the original application, R1 was defined to be partially dependent on R4 and R5, and R4 and R5 were later defined to be the same as R1. The current amendment (by defining R4-R7 to recite certain specific embodiment of R1) breaks such an interdependency between R1 and R4, R5. Those amendments are supported in the original application and claims as filed.



In addition, there is an obvious error with the structure of  in claim 1, as it is well known that sulfur is a divalent atom in the current context. To correct this obvious error, the



structure has been amended to read as  and with the rest of the claim being amended accordingly. No new matter has been added. Claim 15 has been amended to eliminate multiple dependency.

### **35 U.S.C. §112 Issues**

In the Office Action, claims 6-11 were rejected under 35 U.S.C. §112, second paragraph, as being indefinite. Claims 7-10 have now been canceled without prejudice. Applicants further submit that claim 6 is definite because it recites the compounds in their salt forms, which are perfectly acceptable under the U.S. patent laws. Withdrawal of the rejection is respectively requested.

### **Nonstatutory Double Patenting**

In the Office Action, Claims 1-2, 6-11, 15, and 17 were rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over U.S. Pat. No. 6693117, U.S. Pat. No. 6455545 and U.S. Pat. No. 6187792. Applicants hereby file terminal

disclaimers over these mentioned patents to obviate this rejection. Withdrawal of this rejection is respectfully requested.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

A petition for a one month extension of time is being filed herewith, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. A1570-4P US.

Although Applicants believe no excess claim fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. A1570-4P US.

Respectfully submitted,  
/Jianzhong SHEN, Reg.#48076/

---

Name: Jianzhong Shen  
Dated: July 11, 2006  
Reg. No.: 48076  
Phone No.: 302-886-8854  
Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington,  
DE-19850-5437